Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics

Reuters

Yesterday

Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics

Overview

Diagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectations
Company affirms guidance for positive Adjusted EBITDA in Q4 2025
Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansion

Outlook

Biodesix affirms positive Adjusted EBITDA expectation for Q4 2025
Company sees momentum building into 2026

Result Drivers

LUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursement
DEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$28.80 mln	$24.85 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46

Press Release: ID:nGNX1CsNVy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602519547"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602519547\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602519547?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602519547","market":"nz","top_or_hot":-1,"title":"Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics </title></head><body><p><span>Overview</span></p><ul><li><p>Diagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectations</p></li><li><p>Company affirms guidance for positive Adjusted EBITDA in Q4 2025</p></li><li><p>Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansion</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biodesix affirms positive Adjusted EBITDA expectation for Q4 2025</p></li><li><p>Company sees momentum building into 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursement</p></li><li><p>DEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$28.80 mln</p></td><td><p>$24.85 mln (5 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the healthcare facilities &amp; services peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46</p></li></ul><p>Press Release: <span>ID:nGNX1CsNVy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics </title></head><body><p><span>Overview</span></p><ul><li><p>Diagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectations</p></li><li><p>Company affirms guidance for positive Adjusted EBITDA in Q4 2025</p></li><li><p>Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansion</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biodesix affirms positive Adjusted EBITDA expectation for Q4 2025</p></li><li><p>Company sees momentum building into 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursement</p></li><li><p>DEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$28.80 mln</p></td><td><p>$24.85 mln (5 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the healthcare facilities &amp; services peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46</p></li></ul><p>Press Release: <span>ID:nGNX1CsNVy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL1N3YD0B0:1","article_id":"2602519547","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602519547","pubTimestamp":1768216216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung DiagnosticsOverviewDiagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectationsCompany affirms guid","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BDSX":"Biodesix, Inc."},"translate_title":"得益于肺部诊断领域的增长，Biodesix prelim第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDSX":0.9},"content_text":"Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics OverviewDiagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectationsCompany affirms guidance for positive Adjusted EBITDA in Q4 2025Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansionOutlookBiodesix affirms positive Adjusted EBITDA expectation for Q4 2025Company sees momentum building into 2026Result DriversLUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursementDEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growthKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$28.80 mln$24.85 mln (5 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the healthcare facilities & services peer group is \"buy\"Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46Press Release: ID:nGNX1CsNVyFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}